Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model

International Journal of Cancer

Volumn 100, Issue 2, 2002, Pages 140-143

  Simonart, Thierry ^a,b   Boelaert, Johan R ^b   Andrei, Graciela ^c   Van Den Oord, Joost J ^d   Degraef, Chantale ^e   Hermans, Philippe ^f   Noel, Jean Christophe ^a   Van Vooren, Jean Paul ^a   Heenen, Michel ^a   De Clercq, Erik ^c   Snoeck, Robert ^c  

^a ERASME HOSPITAL   (Belgium)

^b General Hospital St Jan   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e FREE UNIVERSITY OF BRUSSELS   (Belgium)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chelation; Desferrioxamine; Iron; Kaposi's sarcoma; Tumor

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON DEXTRAN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEMATOCRIT; HUMAN; HUMAN CELL; IRON CHELATION; IRON DEFICIENCY; KAPOSI SARCOMA; MOUSE; NONHUMAN; NUDE MOUSE; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TUMOR GROWTH; TUMOR XENOGRAFT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; APOPTOSIS; BODY WEIGHT; BROMODEOXYURIDINE; CELL DIVISION; DEFEROXAMINE; HUMANS; IN SITU NICK-END LABELING; IRON; IRON CHELATING AGENTS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; SARCOMA, KAPOSI; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037054928     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10475     Document Type: Article

References (28)

1. The enigmas of Kaposi's sarcoma
2. Kaposi's sarcoma
3. Endemic Kaposi's sarcoma in Africa and local volcanic soils
4. Iron as a potential cofactor in the pathogenesis of Kaposi's sarcoma?
5. Iron in cancer
6. The role of iron in cancer
7. Altered iron metabolism in HIV infection: Mechanisms, possible consequences, and proposals for management
8. Iron induces Bcl-2 expression in human dermal microvascular endothelial cells
9. Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors
10. Enhancement of classic Kaposi's sarcoma growth after intralesional injections of desferrioxamine
11. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone
12. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model
13. An animal model of iron overload and its application to study hepatic ferritin mobilization by chelators
14. Dose response studies using desferrioxamine and orally active chelators in a mouse model
15. Iron overload alters innate and T helper cell responses to Candida albicans in mice
16. Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro
17. Vascular endothelial growth factor/permeability factor is an autocrine growth factor for AIDS-associated Kaposi's sarcoma
18. Upregulation of vascular endothelial growth factor production by iron chelation
19. Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation of HL-60 cells
20. Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice
21. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell
22. Neuroblastoma sensitivity to growth inhibition by desferrioxamine: Evidence for a block in G1 phase of the cell cycle
23. Iron deprivation-induced apoptosis in HL-60 cells
24. Effects of iron deprivation on Mycobacterium avium growth
25. Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts
26. Protection by deferoxamine from endothelial injury: A possible link with inhibition of intracellular xanthine oxidase
27. Ordering the cell death pathway
28. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents